tebu-bio enters agreement with Enzium for Europe

tebu-bio recently signed an agreement with Enzium Inc. (Philadelphia, PA, USA) for the distribution in Enzium - Blog ThumbnailEurope of their protease activity assays.

Enzium has developed a new approach to measure the activity of proteases such as diverse MMPs, ADAMs, Thrombin, Factor Xa, and Furin and the inhibitory effects of drug candidates.

Dr. Diana Hulboy (VP, Marketing and Business Development at Enzium) says: “We are thrilled to collaborate with tebu-bio on the marketing of EnSens® assays throughout the European community, as we believe our new, non-FRET fluorescent technology will change how researchers think about protease activity detection.”

Dr. Ali El Bayâ (tebu-bio, Sales Manager – Proteins & Protein based Products & Services) adds “Enzium’s EnSens® technology is a very promising alternative to classical FRET based protease assays which are used in screenings in drug discovery. The benefits of this new approach in terms of lower signal to noise ratio and higher flexibility in creating longer and more complex protease recognition sites seem obvious to us. We are sure our extensive customer base within the drug discovery community will be keen to use this technology.”

Find out more about Enzium’s products available from tebu-bio.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: